Issue 150 | January 2025
In this issue: Recent US reproductive laws could limit women’s participation in trials, how Pfizer outplayed Starboard, PreP therapies come to the fore, and more.
Issue 149 | December 2024
In this issue: investigating if dry powder inhalers are the key to sustainable respiratory care, the rise of green chemistry, the pharmacy of the future, and more
Issue 148 | November 2024
In this issue: The manufacturing shift to meet growing cell and gene therapy (CGT) demand, applying lessons from the Covid-19 pandemic to address mpox, Opdivo and Keytruda, a ten-year review, and more.
Issue 147 | October 2024
In this issue: Solving adherence issues with prodrugs, examining whether PBMs are to blame for high drugs prices in the US, developing vaccines for Disease X, and more.
Issue 146 | September 2024
In this issue: Developing drugs for metabolic disorders, solving the drug delivery conundrum for Alzheimer’s disease drugs, and the growth of artificial intelligence (AI) in healthcare, and more.
Issue 145 | August 2024
In this issue: Saving abandoned gene therapy programs, exploring the genAI boom in pharma, the evolution of South Korea’s reimbursement administration, understanding the FDA’s latest clinical trial diversity guidance, and more.
Issue 144 | July 2024
UK’s new Netflix-style funding model for antibiotics, the Swiss biotech ecosystem recuperates from financial instability of 2023, how patient advocacy can lead to more successful clinical trials, and more.
Issue 143 | June 2024
In this issue: Lula’s progress plan for Brazil, sizing up the cell and gene therapy landscape in the US, how sham patents are hurting the pharma industry, tracking opioid settlements, and more.
Issue 142 | May 2024
In this issue: Following the RSV therapy and vaccine rollout, understanding molecular glues, using pharmacovigilance for active drug discovery, BARDA’s plans to combat multiple infections, and more.
Issue 141 | April 2024
In this issue: High-profile gene therapies that use AAV vectors, new research into HIV-TB coinfection treatments, traceability technologies for the supply chain, and more.
Issue 140 | March 2024
In this issue: Studying novel obesity drugs, pharma prepares for climate disasters, the CRISPR pipeline accelerates, exploring drug delivery technologies for the opioid crisis, and more
Issue 139 | February 2024
In this issue: Investigating priority review vouchers, tackling fake anti-obesity drugs, major recent advances with cancer vaccines, balancing quality and sustainability in pharma manufacturing, and more.
Issue 138 | January 2024
In this issue: Pharma’s efforts to curb Scope 3 emissions, understanding European Pharmaceutical legislation, predicting the future of cell and gene therapy manufacturing, and looking back at the pharma industry’s performance in 2023.
Issue 137 | December 2023
In this issue: Fixing drug nomenclature to avoid confusing names, gene therapies for sickle cell disease, childproof packaging for drugs, and UK pharma manufacturing gears up for a shake up in 2024
Issue 136 | November 2023
In this issue: Diabetes researchers oppose the regulation of islet transplantation as a biologic in the US, why haemophilia gene therapies are so expensive, how AI will help with trial recruitment.
Issue 135 | October 2023
In this issue: Pharma tries to make more effective IBD drugs, subcutaneous versions give immunotherapies a new life, supporting human touch in clinical trials.
Issue 134 | September 2023
In this issue: Digital jobs in UK life sciences, generative AI changes drug discovery, and how robotics is impacting gene therapy manufacturing.
Issue 133 | August 2023
In this issue: Drug shortages force clinics to ration supplies, AMR drug discovery using a subscription model, AI revolutionizes pharma sales.
Issue 132 | July 2023
In this issue: Artificial intelligence tools for patients, EU funding for British biotech, Analytics for continuous manufacturing, Apple’s play for the metaverse.
Issue 131 | June 2023
In this issue: First generics, managed access programs, navigating RSV vaccine distribution and fixing the drug shortage problem in Europe.
Issue 130 | May 2023
In this issue: mRNA Covid-19 vaccine success drives nanoparticle research, eConsent in clinical trials, digital inhalers, controversies surrounding primate models, and more.
Issue 129 | April 2023
In this issue: Developing drugs for aging, sustainable cleanroom tech, digital therapeutics to improve neurological outcomes, cloud-related advances, and more.
Issue 128 | March 2023
In this issue: Right shoring API production in Europe, the hunt for an Alzheimer’s disease vaccine, key trends of decentralised clinical trials in 2023, and more.
Issue 127 | February 2023
In this issue: CRISPR gene therapy milestones in 2023, analyzing major deal trends in pharma, regulating artificial intelligence use in pharma, and more.
Issue 126 | January 2023
In this issue: The US launch of Humira biosimilars, developing new drugs to strike obesity, exploring ketamine’s use for rare neurological disorders, and more.
Issue 125 | December 2022
In this issue: The UK pharma sector’s wish list for the new PM, the difficult outlook for chronic cardiovascular drug shortages, assessing the value of hemophilia gene therapies, and more.
Issue 124 | November 2022
In this issue: Drug development and manufacturing in outer space, how inflation is driving sustainability in manufacturing, the future of remote regulatory assessments, and more.
Issue 123 | October 2022
The promise of billion-dollar KRAS drugs, exploring nanorobots in drug delivery, foreign investments amplifying the nucleic acid therapeutics field, and more.
Issue 122 | September 2022
In this issue, we take a look at changes at UK’s regulatory body NICE, new therapeutic approaches for prion diseases, and specialty generics production.
Issue 121 | August 2022
In this issue: We take a look at the potential clinical impact of genomic projects, how clinical trials can better measure pain, the evolution of the US Food and Drug Administration’s Orphan Drug program, and more.
Issue 120 | July 2022
In this issue: We examine how delays derailed Covid-19 vaccination campaigns in Africa, China’s rapid progress in developing CAR-T therapies, how the bear market is affecting drug financing, and more.
Issue 119 | June 2022
In this issue: Continuous manufacturing builds on hype, access to CAR-T therapies in Central and Eastern Europe, the emissions targets of pharma and biotech companies, and more.
Issue 118 | May 2022
In this issue: Tackling insulin prices with online deliveries, Covid-19 and flu combo vaccines advance, Big pharma’s gradual retreat on clinical trials in Russia, and more.
Issue 117 | April 2022
In this issue: What the pandemic taught us about delivering essential vaccines, Covid-19 adds further burdens to CAR-T development, what’s next for Sputnik Covid-19 vaccine production, and more.
Issue 116 | March2022
In this issue: Cutting the carbon footprint of pharma’s supply chain, uneven supply patterns hinder US rollout of Covid-19 antivirals, how AI could unlock the medical potential of psychedelics, and more.
Issue 115 | February 2022
In this issue: Mapping the RNA therapeutics R&D landscape in 2022, anaesthesia drugs worst-hit by US drug shortages, Aduhelm qualms continue with Medicare verdict, and more.
Issue 114 | January 2022
In this issue: Challenges in pharmacovigilance for treatments involving multiple drugs, the potential of 3D printing in drug manufacturing, opportunities in value-based pricing, and more.
Issue 113 | December 2021
In this issue: Tackling the rise in illegal online pharmacies caused by drug shortages, how Covid-19 vaccine pricing varies between countries and companies, digitising the supply chain, and more.
Issue 112 | November 2021
In this issue: The ethical dilemma of vaccine boosters, optimising real-world data in the pharma industry, billionaires search for ways to cure ageing, predicting the placebo response, and much more.
Issue 111 | October 2021
In this issue: Unpacking the challenge of complex biologics, using bacteria to fight breast cancer, fighting Covid-19 with llama-derived antibodies, securing the US pharma supply chain, and much more.
Issue 110 | September 2021
In this issue: Cyberattacks to know and learn from, addressing pharmaceutical pollution in European hospitals, the therapeutics treating alcohol use disorder, pushing for a genomics revolution in the UK, and much more.
Issue 109 | August 2021
In this issue: Waiving Covid-19 vaccine patents to speed up vaccination efforts, chickenpox vaccines in the UK, algae proteins spotlight innovation in ophthalmology, fighting black fungus in India, and much more.
Issue 108 | July 2021
In this issue: Lifting the ban on UK blood plasma, alternatives to shark squalene in vaccines, malaria treatments through the ages, and much more.
Issue 107 | June 2021
In this issue: Rethinking the supply chain for a post-pandemic world, treating rare diseases in India, how to get a drug name approved, developing an oral Covid-19 vaccine, and much more.
Issue 106 | May 2021
In this issue: Tackling AMR with antibiotic alternatives, the promise of regenerative medicines, drug dispensing goes digital, ethical and safety considerations facing Human Challenge Trials, and much more.
Issue 105 | April 2021
In this issue: Big Pharma meets Big Tech, preparing for the next pandemic, pharma marketing on social media, the future of mRNA vaccines, and much more.
Issue 104 | March 2021
In this issue: the future of skinny labelling in the generics space, how Henrietta Lacks changed medicine without her consent, charting the rise of antibody-drug conjugates, and much more.
Issue 103 | February 2021
In this issue: spotting new Covid variants with real-time genome surveillance, addressing the threat of AMR, preparing for Amazon Pharmacy, rebuilding Big Pharma’s image, and much more.
Issue 102 | January 2021
In this issue: Joe Biden’s potential for pharma, unlocking the mystery of Hepatitis C, fast-tracking vaccine development, the ethics of achondroplasia, and much more.
Special Issue | Yearbook 2020
In this issue: A collection of some of the biggest stories and longform reads published in Pharma Technology Focus across the past year.
Issue 101 | December 2020
In this issue: The logistics of distributing a Covid-19 vaccine, key characteristics of Phase III trials, predicting vaccine success with AI, the future of plant-based drug development, and much more.
Issue 100 | November 2020
In this issue: Overcoming vaccine hesitancy, diversity in Covid-19 clinical trials, treating chronic pain without pain killers, and much more in an innovative new design format.
Issue 99 | October 2020
In this issue: Inside the manufacturing inspection process, the therapeutic potential of oxytocin, addressing the long-term health effects of Covid-19, and much more..
Issue 98 | September 2020
In this issue: Puberty blockers for transgender youths, pharma’s reliance on horseshoe crab blood, celebrating a century of culture collections, AI as a drug inventor, and much more.
Issue 97 | August 2020
In this issue: The logistics of delivering a Covid-19 vaccine, recruiting participants for clinical trial, a novel approach to tackling AMR, psychedelics in mental health treatment, and much more.
Issue 96 | July 2020
In this issue: Penetrating the blood-brain barrier, the trials and tribulations of the World Health Organization, intellectual property laws in a Covid-19 world, and much more.
Issue 95 | June 2020
In this issue: Re-purposing drugs to treat Covid-19, drug pricing in a pandemic, antitrust issues in pharma, unlocking the benefits of turmeric, and much more.
Issue 94 | May 2020
In this issue: Maximising the tolerability of non-active ingredients, the importance of whistleblowers in pandemics, tracking mumps treatment, and much more.
Issue 93 | April 2020
In this issue: Opioid access around the world, sustainability in pharma, treating chronic Lyme disease, tracking medications in transit, and much more.
Issue 92 | March 2020
In this issue: Anti-fungal innovation, the US opioid crisis enters a new decade, protecting pharma from leaks, and much more.
Issue 91 | February 2020
In this issue: EDS and rare diseases, drug development to treat ageing, ‘just-in-time’ drugs in space, and much more.
Issue 90 | January 2020
In this issue: PrEP access in England, taxing Big Pharma, treating endometriosis, and much more.
Special issue | Yearbook 2019
In this issue: the biggest stories, trends, scandals and innovations in the Pharma industry in 2019.
Issue 89 | December 2019
In this issue: PR in pharma, paediatric drug development, repatriating API manufacturing, the Irish pharma juggernaut, bias in cancer drug trials, and much more.
Issue 88 | November 2019
In this issue: dengue fever vaccine controversy, the problem of manipulated data, fixing a broken drug patent system, non-hormonal menopause treatments and much more.
Issue 87 | October 2019
In this issue: a smart pill bottle designed to help patients keep track of their meds, WHO’s Essential Medicines List, the rise of animal testing alternatives, an upfront payment model for drugs, and much more.
Issue 86 | September 2019
In this issue: public attitudes towards mental health drugs, using real-world data in drug approvals, cystic fibrosis buyers clubs in the UK, and much more.
Issue 85 | August 2019
In this issue: breakthroughs in HIV treatment, understanding drug-resistant TB, the fallout from Teva’s price fixing scandal, tackling unlicensed stem cell clinics, and much more.
Issue 84 | July 2019
In this issue: exploring the potential of the underwater biome in drug development, nationalised drug discovery in the UK, predicting drug failures with AI, and much more.
Issue 83 | June 2019
In this issue: a look back at Scott Gottlieb’s time as FDA commissioner, connecting drugmakers with material suppliers, the pharmaceutical properties of CBD, and much more.
Issue 82 | May 2019
In this issue: the buzz around esketamine, treatments to target memory loss, cannabis in the UK and much more.
Issue 81 | April 2019
In this issue: addressing the issue of snake bites and antivenom, the medicinal potential of illegal drugs, tackling rogue online pharmacies, and much more.
Issue 80 | March 2019
In this issue: the disappearing supply of pink Migraleve in the UK, drug ingredients sourced from corn, using machine learning to accelerate diagnosis and treatment of rare diseases, and much more.
Issue 79 | February 2019
In this issue: knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
Issue 78 | January 2019
In this issue: A new class of cancer combo treatments, antidepressants in the environment, microbiome-based drug development, and more.
Special Issue | Yearbook 2018
In this issue: We revisit the big stories from 2018 to find out how patient health data is transforming the pharma industry.
Issue 77 | December 2018
In this issue: China’s growing pharmaceutical market, antimicrobial resistance, the rise of tech giants in healthcare, and more.
Issue 76 | November 2018
In this issue: HPV vaccine programmes, dominantly inherited Alzheimer’s disease, a unique brain ‘fingerprint’ and more .
Issue 75 | October 2018
In this issue: Making manufacturing work in gene and cell therapies, AI generated compounds, clinical trial transparency in the Americas, and more.
Issue 74 | September 2018
In this issue: Boosting trust in big pharma, the highs and lows of the world’s most expensive drug, gene therapy, and more..
Issue 73 | August 2018
Major investment signals confidence in the search for new products developed from DNA found in soil, a medical milestone for cannabinoids in the US, streamlining clinical research, and more.
Issue 72 | July 2018
Overcoming red tape in China, how to boost adoption of biosimilars in the US, a profile of global health research network TriNetX, unlocking cell-free protein synthesis, and more.
Issue 71 | June 2018
A surge of M&A activity in the biotech space, the history of drug development for mumps, a profile of the Swiss pharmaceutical market, using digital tech to unlock billions in savings for pharma companies, and more.
Issue 70 | May 2018
A toolkit to enhance the user experience for life sciences, the problem of unapproved antibiotics in India, a new taxonomy for traditional Chinese medicine, inside Canada’s Centre for Drug Research and Development, and more.
Issue 69 | April 2018
The world’s pharma manufacturing hotspots, creating a universal flu vaccine, obstacles to improving the treatment of Alzheimer’s disease, the potential of growth drugs, detecting racemisation in drugs, and more.
Issue 68 | March 2018
The benefits of seamless clinical trials, a new functional cure for HIV, using mRNA to target cancer tumours, the potential of magnetic hyperthermia in killing cancerous cells, a look at drug pricing policies around the world, and more.
Issue 67 | February 2018
How cancer drug resistance works, accessing funding for rare diseases, India’s attempt to redefine over the counter drugs, the biotech potential of slipper limpets, Dundee University’s influence in pharma research, and more.
Issue 66 | January 2018
Breaking cancer’s drug addiction, the NHS’ decision to switch from biologics to biosimilars, Elsevier’s common model for data sharing, a generic antiretroviral for HIV/AIDS, the opioid addiction crisis in the US, and more.
Yearbook 2017
We round up the biggest pharma developments and stories from around the globe in 2017, consider the impact Brexit could have on IDMP preparations, take a closer look at the outlook for the pharmaceutical industry in 2018, and more.
Issue 65 | December 2017
Calls for closer ties between the NHS and pharma, Norway’s unique prescription database, a new way to reduce the risk of heart attacks, MDMA’s potential to treat PTSD, a curative compound derived from red sage, and more.
Issue 64 | November 2017
Using drugs after their expiration dates have passed, treating lactose intolerance, a closer look at CARB-X’s work on antibacterial research and development, helping nanomedicines reach their target, radioactive isotopes battling cancer, and more.
Issue 63 | October 2017
UK pharma industry takes NICE to court over price caps, Amazon’s potential to enter the US pharmacy industry, a new platform to capture molecules from fungi, the current state of drug development in osteoporosis, and more.
Issue 62 | September 2017
A new tool to encourage links between industry and academia, blockchain’s applications for pharma, using Zika to attack brain tumour cells, treating MS with nanotechnology, the benefits of publicly funded cancer trials, and more.
Issue 61 | August 2017
The UK’s healthcare spending problem, PhRMA’s new R&D spending requirements, undermining supply chain security by importing foreign drugs, milestone cystic fibrosis trials, a personalised treatment approach for panic disorder, and more.
Issue 60 | July 2017
Solving US drug pricing issues by importing cheaper Canadian drugs, underexplored fields in immuno-oncology, a new temperature-resistant rabies and yellow fever vaccine, the increasingly popularity of adaptive clinical trials, and more.
Issue 59 | June 2017
Challenging the link between innovation and US drug pricing, the impact of Brexit on life sciences companies, a new study on the effects of cognitive-enhancing drugs, using crowdfunding to unlock cancer therapies, and more.
Issue 58 | May 2017
Promising Alzheimer’s drugs in development, potential applications for the hormone kisspeptin, the cost of failed drug candidates, a new app matching patients to clinical trials, pharma packaging trends, and more.
Issue 57 | April 2017
Japan’s pharma industry looks abroad, Trump’s plans for US drug manufacturing, unlocking regenerative medicine, the medical benefits of turmeric, the dangers posed by first-in-human drug trials, and more.
Issue 56 | March 2017
Clinical research in the UK, fighting diabetes with peptides, balancing speed and safety when reviewing new drugs, the potential of shark antibodies to treat Alzheimer’s, Elsevier’s new project to boost innovation, and more.
Issue 55 | February 2017
India’s new drug pricing policy, bringing transparency to pharma industry payments, a UK innovation centre enabling new means of drug discovery, how artificial intelligence is being used in drug development, and more.
Issue 54 | January 2017
Senator Bernie Sanders continues to rail against the pharma industry, why companies pay to prolong patents, a new genomic array helping fight disease in Africa, treating mononucleosis, a new era for ibuprofen, and more.